Acromegaly  >>  octreotide acetate  >>  Phase 3
Welcome,         Profile    Billing    Logout  

8 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
octreotide acetate / Generic mfg.
NCT00128232: Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Completed
3
100
Europe
Octreotide LAR
Novartis
Acromegaly
08/04
 
NCT00225979: Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Completed
3
100
Europe
Octreotide LAR, SMS995
Novartis Pharmaceuticals
Acromegaly
03/05
03/05
NCT00372697 / 2005-003444-53: Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Completed
3
28
Europe
Octreotide acetate 30 mg suspension, Sandostatin LAR
Novartis Pharmaceuticals
Acromegaly
10/07
10/07
NCT00444873: Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Completed
3
38
Europe
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Ipsen
Acromegaly
01/08
01/08
NCT00616551 / 2006-005855-14: Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Completed
3
65
Europe, RoW
C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg, Sandostatin LAR, 30 mg
Ambrilia Biopharma, Inc.
Acromegaly
02/08
02/08
NCT00765323 / 2008-003327-23: Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Terminated
3
169
US, Europe, RoW
Octreotide Implant, somatostatin analogue, Sandostatin LAR Depot
Endo Pharmaceuticals
Acromegaly
02/11
06/11
PAOLA, NCT01137682 / 2009-016722-13: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Completed
3
198
US, Canada, Europe, RoW
Pasireotide, SOM230, octreotide LAR 30mg, lanreotide ATG 120mg
Novartis Pharmaceuticals
Acromegaly
01/13
02/17
NCT00600886 / 2007-001972-36: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Completed
3
358
US, Canada, Europe, RoW
Pasireotide, SOM230, Octreotide
Novartis Pharmaceuticals
Acromegaly
03/16
03/16

Download Options